Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun;7(6):336-46.
doi: 10.1038/nrgastro.2010.58. Epub 2010 May 4.

Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development

Affiliations
Review

Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development

Xavier Sagaert et al. Nat Rev Gastroenterol Hepatol. 2010 Jun.

Abstract

Mucosa-associated lymphoid tissue (MALT) lymphoma, or extranodal marginal zone lymphoma of MALT, is an indolent B-cell non-Hodgkin lymphoma arising in lymphoid infiltrates that are induced by chronic inflammation in extranodal sites. The stomach is the most commonly affected organ, in which MALT lymphoma pathogenesis is clearly associated with Helicobacter pylori gastroduodenitis. Gastric MALT lymphoma has attracted attention because of the involvement of genetic aberrations in the nuclear factor kappaB (NFkappaB) pathway, one of the most investigated pathways in the fields of immunology and oncology. This Review presents gastric MALT lymphoma as an outstanding example of the close pathogenetic link between chronic inflammation and tumor development, and describes how this information can be integrated into daily clinical practice. Gastric MALT lymphoma is considered one of the best models of how genetic events lead to oncogenesis, determine tumor biology, dictate clinical behavior and represent viable therapeutic targets. Moreover, in view of the association of gastric MALT lymphoma with dysregulation of the NFkappaB pathway, this signaling pathway will be discussed in depth in both normal and pathological conditions, highlighting strategies to identify new therapeutic targets in this lymphoma.

PubMed Disclaimer

References

    1. Nat Rev Immunol. 2004 May;4(5):348-59 - PubMed
    1. Haematologica. 2000 Feb;85(2):147-53 - PubMed
    1. Blood. 2005 Dec 15;106(13):4210-6 - PubMed
    1. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2463-8 - PubMed
    1. Gastroenterology. 2000 Nov;119(5):1191-202 - PubMed

MeSH terms